Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Actuate Therapeutics, Inc. ( (ACTU) ).
On May 31, 2025, Actuate Therapeutics presented topline Phase 2 data at the ASCO Annual Meeting, showing that elraglusib combined with gemcitabine/nab-paclitaxel significantly improved median overall survival in metastatic pancreatic cancer patients compared to the control group. The trial met its primary endpoint with a 37% reduction in the risk of death, indicating a favorable risk-benefit profile for the combination treatment. This development could enhance Actuate’s positioning in the oncology market and offer new hope for stakeholders involved in pancreatic cancer treatment.
The most recent analyst rating on (ACTU) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Actuate Therapeutics, Inc. stock, see the ACTU Stock Forecast page.
More about Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment. Their primary product, elraglusib, is a GSK-3β inhibitor being tested in multiple advanced cancer Phase 2 trials, including metastatic pancreatic cancer and Ewing sarcoma.
Average Trading Volume: 54,312
Technical Sentiment Signal: Strong Buy
Find detailed analytics on ACTU stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue